

Company registration number: 08148602

Prescient Biopharma Limited

Unaudited financial statements

31 December 2016

FRIDAY



A6G0J7TV

A06

29/09/2017

#485

COMPANIES HOUSE

Prescient Biopharma Limited

Contents

	Page
Director's report	2
Statement of financial position	3
Notes to the financial statements	4 - 5

Prescient Biopharma Limited

**Director's report
Year ended 31 December 2016**

The director presents his report and the unaudited financial statements of the company for the year ended 31 December 2016.

The company has been dormant as defined in section 1169 of the Companies Act 2006 throughout the year and preceding financial year. It is anticipated that the company will remain dormant for the foreseeable future.

Director


The director who served the company during the year was as follows:

J.A. Denison-Pender

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

This report was approved by the board of directors on 25 April 2017 and signed on behalf of the board by:



A. C. G. McMeeking
Secretary

Prescient Biopharma Limited

**Statement of financial position
31 December 2016**

	Note	2016 £	£	2015 £	£
Current assets					
Debtors	4	1		1	
		<u>1</u>		<u>1</u>	
Net current assets			1		1
Total assets less current liabilities			<u>1</u>		<u>1</u>
Net assets			<u>1</u>		<u>1</u>
Capital and reserves					
Called up share capital			1		1
Shareholders funds			<u>1</u>		<u>1</u>

The company did not trade during the current year or prior year and has not made either a profit or loss.


For the year ending 31 December 2016 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

- The shareholders have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements were approved by the board of directors and authorised for issue on 25 April 2017, and are signed on behalf of the board by:



J.A. Denison-Pender
Director

Company registration number: 08148602

Prescient Biopharma Limited

Notes to the financial statements Year ended 31 December 2016

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is CP House, 97 - 107 Uxbridge Road, Ealing, London, W5 5TL.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Income statement policy

The company is dormant as defined by section 1169 of the Companies Act 2006. The company received no income and incurred no expenditure during the current year or prior year and therefore no income statement is presented within these financial statements. There have been no movements in equity during the current year or prior year.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

4. Debtors

	2016	2015
	£	£
Other debtors	<u>1</u>	<u>1</u>

5. Controlling party

The ultimate controlling party is D. Wildey.

Prescient Biopharma Limited

Notes to the financial statements (continued)
Year ended 31 December 2016

6. Ultimate parent undertaking

As at the Balance Sheet date the immediate parent undertaking is Prescient Healthcare Group (UK) Limited and the ultimate parent undertaking is Grindco 614 Limited. Both of these companies are incorporated in England & Wales.